title: An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease.
abstract: It is generally believed that treatments are available to manage chorea in Huntington's disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and side effect profiles, management of inadequate response to a single drug, and preferred drug when behavioral symptoms comorbid to chorea are present. Because there is lack of an evidence base to inform clinical decision-making, we surveyed an international group of experts to address these points. Survey results showed that patient stigma, physical injury, gait instability, work interference, and disturbed sleep were indications for a drug treatment trial. However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia. All experts chose an APD when comorbid psychotic or aggressive behaviors were present, or when active depression prevented the use of TBZ. However, there was agreement from all geographic regions that both APDs and TBZ were acceptable as monotherapy in other situations. Perceived efficacy and side effect profiles were similar for APDs and TBZ, except for depression as a significant side effect of TBZ. Experts used a combination of an APD and TBZ when treatment required both drugs for control of chorea and a concurrent comorbid symptom, or when severe chorea was inadequately controlled by either drug alone. The benzodiazepines (BZDs) were judged ineffective as monotherapy but useful as adjunctive therapy, particularly when chorea was exacerbated by anxiety. There was broad disagreement about the use of amantadine for chorea. Experts who had used amantadine described its benefit as small and transient. In addition to survey results, this report reviews available chorea studies, and lastly presents an algorithm for the treatment of chorea in HD which is based on expert preferences obtained through this international survey.
authors.affiliation: Department of Neurology, University of Bern, Switzerland;  Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario Canada;  David Geffen School of Medicine at UCLA;  Institute for Systems Biology, Seattle, WA;  Formerly CHDI Foundation, Inc. Presently independent CNS development consultant and  Huntington's Disease Drug Works, Lake Forest Park, WA.
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Burgunder
authors.forename: Mark
authors.initials: M
authors.lastname: Guttman
authors.forename: Susan
authors.initials: S
authors.lastname: Perlman
authors.forename: Nathan
authors.initials: N
authors.lastname: Goodman
authors.forename: Daniel P
authors.initials: DP
authors.lastname: van Kammen
authors.forename: Lavonne
authors.initials: L
authors.lastname: Goodman